Showing 1,521 - 1,540 results of 5,346 for search '(( significant ((clinical decrease) OR (linear decrease)) ) OR ( significantly weaker decrease ))', query time: 0.33s Refine Results
  1. 1521

    Table 3_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

    Published 2024
    “…The clinical relevance assays and experimental validation showed SESN1 as a clinical significance target of miR-183-3p.…”
  2. 1522
  3. 1523

    All data used in the article. by Mustafa Tuşat (21094179)

    Published 2025
    “…It was determined that EO treatment significantly reduced the histopathological damage and the caspase-3 (CASP3) expression level in the lung (p < 0.001).…”
  4. 1524

    Lung injury scoring system. by Mustafa Tuşat (21094179)

    Published 2025
    “…It was determined that EO treatment significantly reduced the histopathological damage and the caspase-3 (CASP3) expression level in the lung (p < 0.001).…”
  5. 1525

    Content of EO administered to rats. by Mustafa Tuşat (21094179)

    Published 2025
    “…It was determined that EO treatment significantly reduced the histopathological damage and the caspase-3 (CASP3) expression level in the lung (p < 0.001).…”
  6. 1526

    Table 1_Effectiveness of conversational script optimization by intelligent consultation robots on daily work efficiency in vaccination clinics.docx by Bei Zhou (5219792)

    Published 2025
    “…</p>Discussion<p>Optimizing the robot’s conversational scripts significantly improved daily operational efficiency in the vaccination clinic. …”
  7. 1527

    Supplementary file 1_The action of ginsenoside Rg1 in patients with carotid atherosclerosis: a controlled clinical trial.docx by Xu Fang (450501)

    Published 2025
    “…We aimed to provide novel insights into safe clinical application of ginsenoside Rg1 for managing cardiovascular and cerebrovascular diseases.…”
  8. 1528
  9. 1529

    Image 1_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.pdf by Yi-Chang Zhao (14080107)

    Published 2025
    “…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”
  10. 1530

    Image 2_Practical utility of meropenem therapeutic drug monitoring: a systematic review of evidence for clinical application.pdf by Yi-Chang Zhao (14080107)

    Published 2025
    “…CRP levels decreased significantly (mean difference = 14.91; 95% CI: 2.79–27.02), while changes in PCT, WBC, and neutrophil ratios were non-significant. …”
  11. 1531

    Table 6_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  12. 1532

    Table 7_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  13. 1533

    Table 5_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  14. 1534

    Table 3_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  15. 1535

    Table 1_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  16. 1536

    Table 2_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  17. 1537

    Table 4_Trends in immune cell profiles of osteomyelitis: a clinical study supported by Mendelian randomization analysis.docx by Zemin Liu (224306)

    Published 2025
    “…Subgroup analysis revealed significantly increased lymphocyte counts and decreased neutrophil counts across all subgroups, except for the mixed infection group. …”
  18. 1538
  19. 1539

    Supplementary file 1_Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.docx by Omar Z. Ameer (8900039)

    Published 2025
    “…Dupilumab displays nonlinear pharmacokinetics, with approximately 61% bioavailability and a prolonged half-life that supports biweekly subcutaneous (SC) administration. Clinical trials have demonstrated significant reductions in asthma exacerbation rates, improvements in forced expiratory volume in one second (FEV<sub>1</sub>), and decreased oral corticosteroid (OCS) dependence in adults and children with moderate-to-severe asthma. …”
  20. 1540

    Supplementary file 2_Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness.docx by Omar Z. Ameer (8900039)

    Published 2025
    “…Dupilumab displays nonlinear pharmacokinetics, with approximately 61% bioavailability and a prolonged half-life that supports biweekly subcutaneous (SC) administration. Clinical trials have demonstrated significant reductions in asthma exacerbation rates, improvements in forced expiratory volume in one second (FEV<sub>1</sub>), and decreased oral corticosteroid (OCS) dependence in adults and children with moderate-to-severe asthma. …”